Your signal. Your price.
Rogan described Colossal Biosciences’ dire-wolf project as editing gray wolves using ancient DNA to recreate dire-wolf traits, while acknowledging debate over whether the animals count as dire wolves. The discussion broadened to how human definitions of species handle genetic variation and engineered animals.
Colossal Biosciences utilizes the Asian elephant genome as a template to engineer woolly mammoth traits rather than attempting exact cloning. Beth Shapiro explains that targeting genetic variants unique to mammoths will produce functional proxies capable of restoring degraded Arctic tundra ecosystems.
Avian species cannot be cloned using somatic cell nuclear transfer due to egg cell accessibility constraints. Beth Shapiro explains that Colossal Biosciences targets the dodo to pioneer bird-specific synthetic biology tools, which can then be deployed to conserve critically endangered living birds.
Colossal Biosciences engineered 20 genetic edits into the gray wolf genome to recreate the robust, light-coated physical traits of the extinct dire wolf. Beth Shapiro notes researchers bypassed original ancient mutations that cause albinism in favor of safe domestic dog variants.
Ben Lamm asserts that entering synthetic biology without a scientific background is a massive advantage because it allows him to ask unbiased questions. His startup Colossal Bioscience is now valued at over $10 billion.
George Church, the co-founder of Colossal and head of genetics at Harvard, champions open-source democratized technology. His lab has generated multiple billion-dollar startups and actively drove down genome sequencing costs.
Colossal initially leveraged LLMs from OpenAI and Anthropic as workflow middleware rather than for biological discovery. Lamm notes that retraining scientists to use Jira was harder than stem cell reprogramming.
Lamm argues that proprietary comparative genomics datasets are far more valuable than the AI models analyzing them. Colossal is constructing a global bio vault system to sequence thousands of genomes across diverse evolutionary paths.
Following advice from investor Bob Nelson, Colossal strictly avoids human applications to prevent FDA regulatory freezes. Lamm believes engineered programmable life will precede any efforts to resurrect extinct human ancestors.
Colossal consistently delivers over 300 gene edits at 90 percent efficiency and is currently testing 1,000 edits. Lamm anticipates that DNA synthesis will eventually replace multiplex gene editing.
Lamm projects that Colossal will birth mammals fully ex utero within 24 months. The technology will handle development from gestation through delivery without requiring a surrogate mother.
Colossal is developing 16 distinct genetic lines to eventually reintroduce tens of thousands of woolly mammoths. Lamm aims to rewild these herds to help restore degraded tundra ecosystems.
Colossal spin-off Astromech is building genomic prediction models to understand why specific traits evolved or stalled. The software will guide traffic for global bio vaults containing millions of sequenced samples.